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The use of combination antibiotic therapy may be beneficial against rapidly emerging resistance in Pseu-
domonas aeruginosa. The aim of this study was to systematically investigate in vitro bacterial killing and
resistance emergence with colistin alone and in combination with imipenem against multidrug-resistant
(MDR) P. aeruginosa. Time-kill studies were conducted over 48 h using 5 clinical isolates and ATCC 27853 at
two inocula (106 and 108 CFU/ml); MDR, non-MDR, and colistin-heteroresistant and -resistant strains
were included. Nine colistin-imipenem combinations were investigated. Microbiological response was exam-
ined by log changes at 6, 24, and 48 h. Colistin combined with imipenem at clinically relevant concentrations
increased the levels of killing of MDR and colistin-heteroresistant isolates at both inocula. Substantial
improvements in activity with combinations were observed across 48 h with all colistin concentrations at the
low inoculum and with colistin at 4 and 16MIC (or 4 and 32 mg/liter) at the high inoculum. Combinations
were additive or synergistic against imipenem-resistant isolates (MICs, 16 and 32 mg/liter) at the 106-CFU
inoculum in 9, 11, and 12 of 18 cases (i.e., 9 combinations across 2 isolates) at 6, 24, and 48 h, respectively, and
against the same isolates at the 108-CFU inoculum in 11, 7, and 8 cases, respectively. Against a colistin-
resistant strain (MIC, 128 mg/liter), combinations were additive or synergistic in 9 and 8 of 9 cases at 24 h at
the 106- and 108-CFU inocula, respectively, and in 5 and 7 cases at 48 h. This systematic study provides
important information for optimization of colistin-imipenem combinations targeting both colistin-susceptible
and colistin-resistant subpopulations.
The world is facing a growing threat from multidrug-resis-
tant (MDR) Gram-negative “superbugs,” such as Pseudomo-
nas aeruginosa, Acinetobacter baumannii, and Klebsiella pneu-
moniae (19, 30, 50). This problem is compounded by a lack of
novel antimicrobial agents in the drug development pipeline
for infections caused by Gram-negative bacteria (30, 31, 50), in
particular those caused by P. aeruginosa (50), and novel agents
with activity against this pathogen may not be available for
approximately 10 years (41). This has led to the reevaluation of
colistin (also known as polymyxin E), a multicomponent cat-
ionic polypeptide antibiotic that entered clinical use in 1959
but was largely replaced by aminoglycosides in the 1970s due to
concerns about the potential for nephrotoxicity and neurotox-
icity (12, 23, 26, 27). Owing to its significant in vitro antibacte-
rial activity against Gram-negative “superbugs,” colistin is of-
ten the only therapeutic option available for the treatment of
infections by these pathogens (1, 27, 35), and therefore, its use
has increased substantially over the past 5 years, especially for
critically ill patients (6, 27).
It is now evident that the concentrations of colistin achieved
in the plasma of critically ill patients with the currently recom-
mended dosage regimens are suboptimal for a significant pro-
portion of patients (13, 43). Unfortunately, increasing the daily
dose may not be an acceptable option, since nephrotoxicity is
a dose-limiting adverse effect and occurs in 30 to 50% of
patients (13, 16, 22). It is therefore not surprising that subop-
timal concentrations cause the emergence of resistance to
colistin, which seriously threatens colistin therapy (45, 48). In
vivo (21, 33) and in vitro (3, 4) studies show the potential for
the rapid emergence of colistin resistance with monotherapy.
The phenomenon of colistin heteroresistance (the presence of
colistin-resistant subpopulations in an isolate considered sus-
ceptible by MIC measurement) (56) has been reported for A.
baumannii (29, 56) and K. pneumoniae (34, 44, 54) but not yet
for P. aeruginosa. Heteroresistance very likely contributes to
the emergence of colistin resistance. The aim of the present
study was to systematically investigate the extent of in vitro
bacterial killing and the emergence of colistin resistance with
colistin alone and in combination with imipenem against P.
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aeruginosa. Key aspects of this study were the use of MDR
isolates with various susceptibilities to colistin and imipenem
(including colistin-heteroresistant isolates first identified in this
study, as well as colistin- and imipenem-resistant strains), ex-
amination of combinations of clinically relevant drug concen-
trations at both low and high inocula, and monitoring of the
emergence of resistance to colistin with real-time population
analysis profiles (PAPs).
(Part of this study was presented at the 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, 12 to 15 September 2009.)
MATERIALS AND METHODS
Bacterial isolates. Five clinical isolates and P. aeruginosa ATCC 27853 (Amer-
ican Type Culture Collection, Manassas, VA) were selected to represent a
mixture of strains susceptible and resistant to colistin and imipenem, colistin-
heteroresistant and nonheteroresistant strains, and multidrug-resistant (MDR)
and non-MDR strains. MDR was defined as diminished susceptibility to at least
two of the following five drug classes: antipseudomonal cephalosporins, anti-
pseudomonal carbapenems, -lactam–-lactamase inhibitor combinations, anti-
pseudomonal fluoroquinolones, and aminoglycosides (40). In addition, all strains
were examined by PCR for the presence of genes encoding cephalosporinases
and carbapenemases, i.e., IMP-, VIM-, NDM-, KPC-, CTX-M-, SHV-, and
CMY-type -lactamases (47, 58). The isolates are described in detail in Table 1.
All clinical isolates were collected from patients with cystic fibrosis, had different
pulsed-field gel electrophoresis patterns, and were considered unrelated accord-
ing to the criteria established by Tenover et al. (53). The MICs of colistin and
imipenem were determined for each isolate in four replicates in cation-adjusted
Mueller-Hinton broth (CAMHB; containing 23.0 mg Ca2/liter and 12.2 mg
Mg2/liter; Oxoid, Hampshire, England) by broth microdilution (10). Isolates
were stored in tryptone soy broth (Oxoid) with 20% glycerol (Ajax Finechem,
Seven Hills, NSW, Australia) at 80°C in cryovials (Simport Plastics, Beloeil,
Quebec, Canada).
Antibiotics. Colistin sulfate (lot 109K1574; 23,251 U/mg) was purchased from
Sigma-Aldrich, St. Louis, MO. Colistin (sulfate) was employed in the current
study because it is the active antibacterial agent formed in vivo after adminis-
tration of its inactive prodrug, colistin methanesulfonate (CMS) (5). Imipenem
(Primaxin; batch K5942) was purchased from Merck Sharp & Dohme, NSW,
Australia. Stock solutions of each antibiotic were prepared according to the
respective manufacturer’s instructions immediately prior to each experiment in
order to minimize loss from degradation; then the solutions were sterilized by
filtration with a 0.22-m-pore-size Millex-GP filter (Millipore, Bedford, MA).
PAPs. The possible existence of colistin-resistant subpopulations at baseline
was determined via population analysis profiles (PAPs) (inoculum, 108 CFU/
ml). Colistin heteroresistance was defined as the existence, in a colistin-suscep-
tible isolate (i.e., MIC, 2 mg/liter) of subpopulations that were able to grow in
the presence of 2 mg/liter colistin in the PAPs. Samples of bacterial cell
suspensions (50 l), appropriately diluted with saline, were spirally plated onto
Mueller-Hinton agar (Media Preparation Unit, The University of Melbourne,
Parkville, Australia) impregnated with colistin (0, 0.5, 1, 2, 3, 4, 6, 8, or 10
mg/liter) by using an automatic spiral plater (WASP; Don Whitley Scientific,
West Yorkshire, United Kingdom). Colonies were counted using a ProtoCOL
colony counter (Synbiosis, Cambridge, United Kingdom) after 24 h of incubation
(48 h for plates with small colonies) at 35°C; the limit of detection was 20
CFU/ml (equivalent to 1 colony per plate), and the limit of quantification (LOQ)
was 400 CFU/ml (equivalent to 20 colonies per plate), as specified in the Pro-
toCOL manual. Real-time PAPs for colistin were also conducted at the end of
time-kill studies (see below).
Time-kill studies. To explore the antimicrobial activities of colistin and imi-
penem combinations, time-kill studies with each antibiotic alone or in combina-
tion were conducted on all isolates at two different starting inocula (106 and
108 CFU/ml). For monotherapy with colistin or imipenem, 2-fold multiples of
the MIC (0.25 to 64 MIC) were employed for susceptible isolates. For the
colistin-resistant isolate (19147 n/m; MIC, 128 mg/liter), a single colistin concen-
tration of 32 mg/liter was employed. Imipenem concentrations of 1, 8, and 32
mg/liter were used for imipenem-resistant isolates. In combination experiments,
both antibiotics were studied at concentrations of 0.5, 4, and 16 MIC for
susceptible isolates; for resistant isolates, concentrations of 1, 4, and 32 mg/liter for
colistin and 1, 8, and 32 mg/liter for imipenem were employed. In total, nine
colistin-imipenem combinations were examined for each isolate at each inoculum.
Prior to each experiment, isolates were subcultured onto horse blood agar
(Media Preparation Unit) and were incubated at 35°C overnight. One colony was
then selected and grown overnight in 10 ml CAMHB at 37°C; from this colony,
an early-log-phase culture was obtained. Each antibiotic was added alone or in
combination to 20 ml of a log-phase broth culture of approximately 106 or 108
CFU/ml to yield the desired concentrations. Each 20-ml culture was placed in a
sterile 50-ml polypropylene tube (Greiner Bio One) and was incubated in a shaking
water bath at 37°C. Serial samples (100 l) were collected aseptically for viable-cell
counting at 0, 0.5, 1, 2, 4, 6, 24, and 48 h and for PAPs at 48 h (see above) for all
experiments involving colistin (including combination arms) and for viable-cell
counting only at 0, 1, 2, 4, 6, 24, and 48 h for experiments with imipenem alone.
Immediately after sampling and serial dilution, 50 l of the bacterial cell suspension
was spirally plated onto nutrient agar with enumeration after 24 h of incubation (48 h
for plates with small colonies) as described under “PAPs” above.
Pharmacodynamic (PD) analysis. Microbiological responses to monotherapy
and combination therapy were examined using the log change method, compar-
ing the change in bacterial counts (log10 CFU/ml) from that at 0 h [log10(CFU0)]
to that at a given time (t) (6, 24, or 48 h) [log10(CFUt)], as follows: log change 
log10(CFUt)  log10(CFU0).
Single antibiotic or combination regimens causing a reduction of 1 log10
CFU/ml from the initial inoculum at 6, 24, or 48 h were considered active. We
considered synergy to be indicated by a 2-log10 CFU/ml-lower bacterial count
with the combination than with its most active component at the specified time
(42); additivity was defined by a 1- to 	2-log10 CFU/ml-lower bacterial count
with the combination.
RESULTS
Microbiological response. The various susceptibilities of the
isolates to colistin are evident in the PAPs obtained prior to
TABLE 1. MICs for the P. aeruginosa isolates used in this study
Isolate
MIC (mg/liter)a Cephalosporinase and
carbapenemase typing MDR
b
Colistin Imipenem
ATCC 27853c 1 2 Negative No
19147 n/m 128 4 IMP and CTX-M positived Yes
19056 muc 0.5 4 Negative Yes
20509 n/mc 0.5 1 Negative No
19271 n/mc 2 32 Negative Yes
20891 n/mc 1 16 Negative Yes
a CLSI breakpoints for colistin were 2 mg/liter for susceptibility, 4 mg/liter for intermediacy, and 8 mg/liter for resistance. For imipenem, the breakpoints were
4 mg/liter for susceptibility, 8 mg/liter for intermediacy, and 16 mg/liter for resistance (10).
b Defined as diminished susceptibility to 2 of the following 5 drug classes: antipseudomonal cephalosporins, antipseudomonal carbapenems, -lactam–-lactamase
inhibitor combinations, antipseudomonal fluoroquinolones, and aminoglycosides (40).
c Colistin heteroresistant. Heteroresistance to colistin was defined as the existence, in an isolate for which the colistin MIC was 2 mg/liter, of subpopulations able
to grow in the presence of 2 mg/liter colistin (55).
d Contains genes encoding an IMP-type carbapenemase and a CTX-M-type ESBL.
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colistin treatment (Fig. 1). Representative time-kill profiles for
colistin and imipenem monotherapy and combination therapy
are shown in Fig. 2 (inoculum, 106 CFU/ml) and 3 (inocu-
lum, 108 CFU/ml). Log changes in viable cell counts at each
inoculum with clinically relevant colistin concentrations are
presented in Tables 2 and 3. Additional time-kill and log
change data are presented in the supplemental material. At the
106-CFU/ml inoculum, regrowth was observed to various ex-
tents for all susceptible isolates at 48 h with colistin mono-
therapy with the majority of concentrations. Regrowth with
imipenem monotherapy at concentrations of 4 or 8 MIC
was more variable and substantially less for susceptible isolates
at 48 h, even when extended-spectrum -lactamases (ESBLs)
were present. An inoculum effect with colistin monotherapy
was generally observed (Fig. 2 and 3, left). Killing by imipenem
was generally slightly slower at the high inoculum than at the
low inoculum, although the extents of reduction in bacterial
counts (log10 CFU/ml) were comparable at the two inocula
(Fig. 2 and 3).
Isolates susceptible to both colistin and imipenem. At the
106-CFU/ml inoculum, the addition of colistin at 0.5 MIC to
imipenem (all concentrations) resulted in additivity or synergy
at 6 h in 7 of 9 cases (i.e., 3 combinations against 3 isolates),
achieving a 2- to 3-log10 greater kill than that with the most
active equivalent monotherapy, and undetectable bacterial
counts in many cases (Table 2 and Fig. 2). By 24 or 48 h,
improvements in activity with combination therapy over that
with the most active monotherapy (usually imipenem) were
modest, particularly when only clinically relevant concentra-
tions of colistin (0.5 or 4 MIC) were considered. Of the 27
cases (i.e., 9 combinations against 3 isolates), 7 at 24 h and 8 at
48 h showed additivity or synergy, although only 1 case resulted
in activity (i.e., 1-log10 kill) if equivalent monotherapy with
either drug was inactive. A similar pattern of activity was ob-
served at the 108-CFU/ml inoculum. For ATCC 27853, com-
binations containing colistin at 4MIC provided an additional
2-log10 kill over that with active monotherapy at 6 h. Against
all three isolates, there were 10 and 9 cases of additivity/
synergy at 24 and 48 h, respectively, mostly involving colistin at
4 or 16 MIC (Table 2).
Imipenem-resistant isolates. For the two imipenem-resis-
tant isolates (19271 n/m and 20891 n/m), there was no evidence
of carbapenemase activity; most likely, an alternative resis-
tance mechanism, such as the loss of major outer membrane
proteins, was present. At the low inoculum, combination ther-
apy resulted in substantial improvements in bacterial kill with
all colistin concentrations across 48 h. At 6 h, additivity/synergy
occurred in 9 of 18 cases (i.e., 9 combinations across 2 isolates),
predominantly against isolate 19271 n/m; additivity/synergy oc-
curred with combinations containing colistin at all concentra-
tions and produced additional reductions of 2- to 6-log10
CFU/ml over that with usually active colistin monotherapy
(Table 3 and Fig. 2). In 5 of 6 cases involving colistin at 4 or
16 MIC against 19271 n/m, bacterial counts were reduced to
below the limit of detection (i.e., 20 CFU/ml). Substantial
improvements in activity against both isolates were also ob-
served at 24 and 48 h at all colistin concentrations. Additivity/
synergy occurred in 11 and 12 of 18 cases at 24 and 48 h,
respectively, resulting in an additional 1- to 4-log10 kill at
24 h and 2.5-log10 kill at 48 h over that with monotherapy
(Table 3 and Fig. 2). Interestingly, the combinations of colistin
at 0.5, 4, or 16 MIC with imipenem at 32 mg/liter each
reduced the bacterial loads of both isolates to below the limit
of detection at 24 h; the maximum reduction in bacterial
counts (log10 CFU/ml) at 24 h with colistin monotherapy at
16 MIC was 4.5. Improvements in activity with combina-
tion therapy at the high inoculum also occurred at all time
points but were essentially restricted to combinations contain-
ing colistin at 4 or 16 MIC. Ten of 12 cases at 6 h contain-
ing colistin at 4MIC (Table 3) or 16MIC (data not shown)
showed additivity or synergy. At 24 and 48 h, the addition of
imipenem at all concentrations to colistin at 4 or 16 MIC
produced additivity/synergy in more than half of all cases and
substantially improved the activity over that with each antibi-
otic alone (by as much as 4-log10 kill).
Colistin-resistant isolate. Bacterial killing at the 106-
CFU/ml inoculum was substantially enhanced at 24 h: all com-
binations tested were additive or synergistic, and only one
combination (colistin at 1 mg/liter plus imipenem at 0.5
MIC) was inactive (Table 3). The addition of all colistin con-
centrations to imipenem at 4 or 16MIC produced3.5- to
4.5-log10 kill at 24 h, substantially higher than that with equiv-
alent imipenem monotherapy. At 48 h, all colistin concentra-
tions in combination with imipenem at 4 MIC were syner-
gistic (2- to 4-log10 kill) and substantially improved activity
over that with equivalent monotherapy. The addition of colis-
tin at 32 mg/liter to imipenem (all concentrations) was additive
or synergistic at a substantially earlier time (6 h), with 1- to
2-log10 greater kill than that with equivalent imipenem mono-
therapy (overall kill, 3 log10 CFU/ml). At the high inoculum,
additivity was achieved at 6 h with all combinations containing
colistin at 4 mg/liter (Table 3) and 32 mg/liter (data not
shown), and activity was enhanced by 1-log10 kill over that
with imipenem monotherapy. Eight of 9 combinations at 24 h
and 7 of 9 combinations at 48 h were additive or synergistic,
encompassing all colistin concentrations and in many cases
FIG. 1. Baseline PAPs of the reference strain and all clinical iso-
lates at an initial inoculum of 108 CFU/ml. The y axis starts from the
limit of detection, and the LOQ is indicated by the dashed horizontal
line.
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resulting in additional reductions of 1 log10 to 4 log10
CFU/ml over that with the most active monotherapy (imi-
penem at 16 MIC). This enhancement of activity was partic-
ularly evident with combinations containing colistin at 4 or 32
mg/liter, and on two occasions, when colistin was combined
with imipenem at 16 MIC, no viable bacteria were detected
at 48 h.
Emergence of colistin resistance. For the 4 colistin-hetero-
resistant isolates (Table 1), the proportion of resistant sub-
populations at 108 CFU/ml ranged from 2.2  107 to 4.7 
103 (Fig. 1). With colistin monotherapy against isolates sus-
ceptible to both colistin and imipenem, real-time PAPs per-
formed at 48 h in the time-kill studies demonstrated increases
in colistin-resistant subpopulations at both the low and high
inocula with clinically relevant colistin concentrations (exam-
ples are shown in Fig. 2 and 3; see also the supplemental
material); no such increase was observed with isolate 19056
muc at the high inoculum. Against imipenem-resistant isolate
19271 n/m, colistin concentrations of 0.25 to 64MIC at the
low inoculum and 1 to 64 MIC at the high inoculum re-
sulted in nearly 100% of the remaining cells at 48 h growing in
the presence of 10 mg/liter colistin. In contrast, no increase in
colistin-resistant subpopulations was observed for the imi-
penem-resistant isolate 20891 n/m at either inoculum. Combi-
FIG. 2. (Left) Representative time-kill curves with various clinically relevant concentrations of colistin (Col) and imipenem (Imi) alone and in
combination at an inoculum of106 CFU/ml. (Right) PAPs at baseline (0 h) and after 48 h of exposure to colistin monotherapy, colistin-imipenem
combination therapy, or neither antibiotic (control). (A) 19147 n/m (colistin resistant, imipenem susceptible, MDR); (B) 20509 n/m (susceptible
to colistin and imipenem, non-MDR); (C) 20891 n/m (colistin susceptible, imipenem resistant, MDR). The y axis starts from the limit of detection,
and the LOQ is indicated by the dashed horizontal line.
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nation therapy against colistin-susceptible isolates generally
had little effect on the proportion of colistin-resistant subpopu-
lations at 48 h at either inoculum; the shapes of the PAPs were
very similar to those obtained with equivalent colistin mono-
therapy (Fig. 2 and 3).
DISCUSSION
Although colistin has been commercially available for more
than 50 years (27), reliable PK/PD data have emerged only
recently. Population PK studies have shown that plasma colis-
tin concentrations achieved with currently recommended CMS
dosage regimens are likely to be suboptimal for many patients,
typically generating average steady-state plasma colistin con-
centrations of 2 to 3 mg/liter, with some patients achieving
concentrations as high as 10 mg/liter (13, 18, 24, 28, 32, 43).
Increasing the daily dose of CMS for such patients may not be
an option, since nephrotoxicity, which occurs in 30 to 50% of
patients (16, 22), is a dose-limiting adverse effect. Given these
circumstances and the current last-line status of colistin ther-
apy, we chose to examine not only synergy but also additivity,
since even a relatively small increase in activity with combina-
tion therapy may be beneficial for patient care. Because colis-
FIG. 3. (Left) Representative time-kill curves with various clinically relevant concentrations of colistin (Col) and imipenem (Imi) alone and in
combination at an inoculum of108 CFU/ml. (Right) PAPs at baseline (0 h) and after 48 h of exposure to colistin monotherapy, colistin-imipenem
combination therapy, or neither antibiotic (control). (A) 19147 n/m (colistin resistant, imipenem susceptible, MDR); (B) 20509 n/m (susceptible
to colistin and imipenem, non-MDR); (C) 20891 n/m (colistin susceptible, imipenem resistant, MDR). The y axis starts from the limit of detection,
and the LOQ is indicated by the dashed horizontal line.
5138 BERGEN ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
tin is almost entirely unbound in CAMHB (3), colistin concen-
trations of 0.5 and 4 MIC for isolates with MICs of 1
mg/liter and 16 MIC for isolates with MICs of 0.5 mg/liter
(1 and 4 mg/liter for colistin-resistant isolates) used in our
study are clinically relevant, even assuming that binding of
colistin by plasma in patients is similar to that in animals (i.e.,
50% bound) (25). Considering the effect of protein binding,
all the imipenem concentrations employed are readily
achieved in plasma (49).
Because some data show that the activities of both colistin
(8) and imipenem (36) are attenuated at high inocula com-
pared to those at low inocula, experiments were conducted at
inocula of both 106 and 108 CFU/ml. An inoculum effect
was generally observed for colistin monotherapy, whereas no
obvious inoculum effect was present for imipenem (Fig. 2 and
3). Regrowth of all isolates was observed with colistin mono-
therapy, even at colistin concentrations well above those that
can safely be achieved clinically. Similar regrowth with colistin
(or polymyxin B) monotherapy has been observed for colistin-
susceptible P. aeruginosa both in vitro (4, 8, 15, 51) and in vivo
(21). For A. baumannii and K. pneumoniae, regrowth following
colistin monotherapy has been attributed to the amplification
of colistin-resistant subpopulations (11, 44, 52), with colistin
heteroresistance reported in both species (17, 29, 44, 54). We
have reported here, for the first time, colistin heteroresistance
in P. aeruginosa. The emergence of colistin resistance following
colistin monotherapy has been reported previously for P.
aeruginosa at both low and high inocula (4, 8), and a similar
phenomenon was observed in the present study for all isolates
except 20981 n/m. While P. aeruginosa can undergo adaptive
resistance to polymyxins (14), the presence of colistin hetero-
resistance at baseline and the changes in PAPs after treatment
suggest that regrowth following colistin monotherapy may be
due to amplification of preexisting colistin-resistant subpopu-
lations. This possibility suggests that care is required with colis-
tin monotherapy against P. aeruginosa, even where isolates
appear susceptible on the basis of MICs.
The addition of imipenem to colistin at both inocula gener-
ally resulted in substantial improvements in bacterial killing
over that with equivalent monotherapy against MDR P. aerugi-
nosa isolates resistant to either antibiotic, even when ESBLs
were present. The improvements in activity against these iso-
lates were observed across the 48-h duration, with all colistin
concentrations at the low inoculum and with colistin at 4 and
16MIC (or 4 and 32 mg/liter) at the high inoculum. Notably,
the total reductions in bacterial counts (log10 CFU/ml)
achieved with combinations containing lower colistin concen-
trations (0.5 and 4 MIC or 1 and 4 mg/liter) were on many
occasions similar in magnitude to the reductions achieved with
combinations containing colistin at 16 MIC, particularly at
the 106-CFU/ml inoculum (Table 3). This suggests that com-
binations of colistin and imipenem containing clinically rele-
vant colistin concentrations may be as effective as combina-
tions containing higher concentrations against MDR isolates
when resistance to either drug is present. This is an important
result, given that colistin-induced nephrotoxicity is a dose-
limiting adverse effect.
The benefits of the addition of imipenem to colistin for
overall antibacterial activity were less pronounced against the
three isolates susceptible to both antibiotics and were generally
restricted to improvements in initial kill, i.e., up to 6 h (Table
2). Because a proportion of patients will achieve only low
plasma colistin concentrations with the currently recom-
mended dosage regimens (13, 43), the combination of colistin
TABLE 2. Log changes in viable cell counts at 6, 24, and 48 h with various clinically relevant concentrations of colistin and imipenem against
three P. aeruginosa isolates susceptible to both antibioticsa
a Col, colistin; Imi, imipenem. A gray background indicates activity (a reduction of 1 log10 CFU/ml below the initial inoculum); a green background indicates
synergy (a 2-log10 decrease in the number of CFU/ml with the combination from that with its most active component); and a red background indicates additivity (a
1.0- to 	2-log10 decrease in the number of CFU/ml with the combination from that with its most active component).
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and imipenem at the commencement of therapy may help to
quickly reduce bacterial levels so as to facilitate clearance by
the immune system.
Previous time-kill studies have examined colistin in combi-
nation with carbapenems against P. aeruginosa (2, 9, 38, 39,
46). These studies examined colistin with imipenem, mero-
penem, or doripenem at a single inoculum (106 or 107 CFU/
ml), though the emergence of colistin resistance was not ex-
amined (e.g., by use of PAPs). The present study is the first to
investigate the emergence of colistin resistance with colistin
combination therapy. In the present investigations, in cases
where the combination led to extensive killing at 48 h, mean-
ingful interpretation of the PAPs was not possible (e.g., Fig.
2B, colistin at 4 MIC as monotherapy and in combination
with imipenem at 4 MIC). When bacterial numbers at 48 h
were comparable, changes in PAPs with combination therapy
generally mirrored those observed with equivalent exposure to
colistin as monotherapy. However, in both the present study
and previously reported studies (2, 9, 38, 39, 46), static con-
centrations and the instability of carbapenems in aqueous me-
dia may have contributed to regrowth and the emergence of
colistin resistance at 48 h (20). Thus, it will be important to
further assess the utility of these combinations against a range
of isolates with various susceptibilities (including heteroresis-
tant strains) in dynamic in vitro models and in vivo.
Two possible reasons for the enhanced pharmacodynamic
effect observed with the combination of colistin and imipenem
are subpopulation synergy and mechanistic synergy, as pro-
posed previously (7). Subpopulation synergy involves one drug
killing the subpopulation(s) resistant to the other drug, and
vice versa. Four of the six isolates in the present study were
colistin heteroresistant (Table 1), indicating the existence of
colistin-resistant subpopulations prior to therapy. In addition,
the four imipenem-susceptible isolates were imipenem hetero-
resistant (while the MIC was 4 mg/liter, subpopulations grew
in the presence of 4 mg/liter imipenem [data not shown]).
Another possibility is mechanistic synergy, whereby colistin
and imipenem, acting on different cellular pathways, each in-
crease the rate or extent of killing of the other drug. In Gram-
negative bacteria, carbapenems must first gain entry into the
periplasmic space in order to bind to critical penicillin-binding
proteins located on the cytoplasmic membrane (37, 55). A
number of resistance mechanisms may operate to limit the
concentration of carbapenems in the periplasm, including the
presence of carbapenem-hydrolyzing enzymes and the loss of
outer membrane proteins (55). Polymyxins cause considerable
permeabilization of the outer membrane (57). It is possible
that the effect of colistin on membrane permeability results in
substantially increased concentrations of imipenem in the
periplasm and improved bactericidal activity. Subpopulation
and mechanistic synergies are not mutually exclusive; both may
operate simultaneously. Further studies, including mechanism-
based mathematical modeling, to investigate the mechanism(s)
TABLE 3. Log changes in viable cell counts at 6, 24, and 48 h with various clinically relevant concentrations of colistin and imipenem against
one colistin-resistant, imipenem-susceptible isolate and two colistin-susceptible, imipenem-resistant isolates of P. aeruginosaa
a Col, colistin; Imi, imipenem. A gray background indicates activity (a reduction of 1 log10 CFU/ml below the initial inoculum); a green background indicates
synergy (a 2-log10 decrease in the number of CFU/ml with the combination from that with its most active component); and a red background indicates additivity (a
1.0- to 	2-log10 decrease in the number of CFU/ml with the combination from that with its most active component). For colistin-resistant isolate 19147 n/m, synergy
or additivity was compared with imipenem monotherapy only.
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underpinning the enhanced pharmacodynamic activity ob-
served are ongoing.
In the battle against rapidly emerging bacterial resistance in
Gram-negative “superbugs,” rational approaches to the use of
combinations of existing antibiotics may be very beneficial. To
the best of our knowledge, this is the first systematic study on
the PD of colistin in combination with imipenem against P.
aeruginosa, including MDR and colistin-heteroresistant strains,
at both low and high inocula. Clinically relevant concentrations
of colistin in combination with imipenem substantially in-
creased bacterial killing against MDR P. aeruginosa isolates at
both inocula when isolates were resistant to either antibiotic.
Further investigations in in vitro pharmacodynamic systems,
animal infection models, and clinical studies are warranted to
optimize colistin-imipenem combinations targeting both colis-
tin-susceptible and colistin-resistant subpopulations.
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